H.C. Wainwright raised the firm’s price target on Akebia to $7.50 from $6 and keeps a Buy rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia reports Q2 EPS (4c), consensus (5c)
- Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Is AKBA a Buy, Before Earnings?
- Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
- Akebia, CSL Vifor enter termination agreement of the Vafseo license agreement